M&A in the Chemical Industry
Navigating Uncertainty While Unlocking Strategic Opportunities
Wolfgang Kazmierowski and Christian Dehm, DC Advisory
Mergers and acquisitions (M&A) are both a driver and a reflection of consolidation in the chemical industry. They allow companies to adapt to a challenging environment, leverage synergies and strengthen their market position. Consolidation in the industry will continue, particularly in segments with persistent margin pressure, but also where investors can benefit from long-term trends such as sustainability and innovation.
The global chemical M&A market is facing a period of significant complexity. Investor confidence has been unsettled by a mix of geopolitical tensions, inflation, and regulatory shifts, creating a cautious environment for dealmaking. While general market sentiment remains mixed, we believe both investors and sellers are active in principle.
Financial sponsors with dry powder are scanning the market for the right opportunities, while several large chemical groups are preparing to divest non-core assets as part of broader portfolio restructuring.
Read more with free registration
Register now for free and get full access to all exclusive articles from chemanager-online.com. With our newsletter we regularly send you top news from the chemistry industry as well as the latest e-issue.
Company

DCAT - Drug, Chemical & Associated Technologies AssociationOne Union St., Suite 208
Robbinsville
US
most read

Lead or Lag: Europe’s AI Materials Race
How AI and Robotics are reshaping the race for materials discovery.

Pharma 4.0—the Key Enabler for Successful Digital Transformation in Pharma
Part 3: Seven Theses for successful Digitalization in Pharma

Q1 2025 Chemical Industry: Diverging Trends
The first quarter of 2025 highlights a continued divergence between the European and US chemical industries.

Relocation of Chemicals Production Footprint in Full Swing
A new Horváth study based on interviews with CxOs of Europe’s top chemical corporations reveals: The majority of board members expects no or only weak growth for the current year.

Pharma 4.0 – the Key Enabler for Successful Digital Transformation in Pharma
Part 1: Building a Business Case for Pharma 4.0











